New cancer drugs added to HK’s drug formulary

Patients using these drugs will pay only standard fees.

The Hospital Authority (HA) has announced that two cancer drugs have been added to the Special Drug category of the Hospital Authority Drug Formulary (HADF).

These drugs, approved under the new “1+” registration mechanism, are oral targeted therapies for treating metastatic colorectal cancer and will be available to patients who cannot use conventional chemotherapy.

Patients using these drugs will pay only standard fees. About 300 patients are expected to benefit each year, with subsidies totaling around $12m.

“With the ‘1+’ mechanism now in effect, the number of drugs successfully registered in Hong Kong would increase, thus enabling clinicians and patients to have more choices for drug treatment,” said William Chui, chief pharmacist at the HA.

He added that the HA is reviewing its drug listing process to speed up future approvals and reduce patient costs.

Moreover, the HA is also preparing to add a third new drug for paroxysmal nocturnal hemoglobinuria to the HADF, with a decision expected in the coming months.

Also Read

Braillic’s AR tech helps brain surgeons see through the walls

PolyU, GCBCOA launches Electronic Painting for Breast Cancer

Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

I want to download the media kit